echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Systemic inflammation scores are associated with survival prognosis in patients with brain metastasis tumors

    Br J Cancer: Systemic inflammation scores are associated with survival prognosis in patients with brain metastasis tumors

    • Last Update: 2021-01-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Brain metastatic tumor (BMs) as a common solid cancer, is a life-threatening complication.
    immunosuppressor therapy has now shown activity on BM.
    , asymptomatic BM patients were more clinically effective than patients with neurological symptoms who needed steroid treatment.
    systemic inflammatory scores, including the ratio of neutral granulocytes to lymphocytes (NLR), white blood cells to lymphocytes (LLR), plate plate and lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and C-reactive protein/albumin ratio (CRP/Alb) have been shown to affect tumor control and ultimately the survival prognosis of patients with extracranial metastatic cancer.
    addition, recently identified systemic inflammatory markers, including pre-treatment CRP, NLR, and MLR, were associated with progression-free survival (PFS) and overall survival (OS) in patients treated with immuno-checkpoint inhibitors.
    systemic inflammation scores were associated with the condition of extracranial diseases, however, no studies have been conducted to reveal the prognostic effects of systemic inflammation scores in the BM patients' queue.
    , the study was designed to analyze the correlation between systemic inflammatory scores such as NLR, LLR, PLR, MLR, and CRP/Alb and the prognostication of survival in BM patients.
    researchers, who had a systemic inflammation score associated with the overall survival rate of patients, collected 1,250 newly diagnosed patients with brain metastasis tumors from the Vienna Brain Transfer Registry.
    studies showed that patients with intracranial metastatic cancer had higher PLR and CRP/Alb scores, while 20 points were lower for noncranial metastasis.
    NLR, LLR, PLR, MLR, and CRP/Alb correspond to a patient's longer total lifetime (OS).
    in multivariable analyses with hierarchical prognossis, NLR, LLR, PLR, MLR, and CRP/Alb remain independent OS-related factors in BM diagnostics.
    , the results showed that systemic inflammatory scores such as NLR, LLR, PLR, MLR, and CRP/Alb were associated with OS in BM patients.
    researchers have also raised the need for further exploration of relevant immunomodulation therapies.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.